Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jun 28, 2023; 29(24): 3855-3870
Published online Jun 28, 2023. doi: 10.3748/wjg.v29.i24.3855
Table 1 Patients characteristics
Characteristics
Values (n = 164)
Male/Female119/45
Age (yr)34.3 ± 12.7
Thalidomide dosage mg/kg/d1.5 (0.3-2.9)
White blood cell ( 109/L)6.2 ± 2.7
Peripheral neuropathy59 (36%)
Duration of thalidomide treatment (m)17.2 (1-60)
Table 2 Univariate analyses of factors associated with thalidomide-induced peripheral neuropathy
SNP
Gene
Minor allele
Main allele
OR
95%CI
P value
rs1353248IL-12TC8.9832.497-30.900.0004
rs6265BDNFTC3.1501.546-6.0730.001
rs2030324BDNFGA3.1641.561-6.4340.001
rs11030104BDNFGA3.0911.525-5.9600.001
rs10991419ABCA1TC3.8331.521-8.9260.002
rs7795841ABCB1GT4.3331.371-13.390.014
rs2575876ABCA1AG2.5591.306-5.2090.007
rs3918249MMP9TC3.8001.208-10.500.016
rs7795846ABCB1AG3.6901.155-10.250.020
rs62447181IKZF1AG2.9330.763-9.5140.096
rs11030100BDNFGT2.2051.074-4.4300.030
rs2777795ABCA1AG1.8300.793-4.1140.09
rs12718731IKZF1GA2.4710.686-8.3280.1
rs34165419ABCA1TC2.5640.664-10.410.1
Table 3 Performance of the models for training set (all features)
Model
Precision
Sensitivity
Specificity
Accuracy
AUROC
F1 score
XGBoost0.90410.940.9620.9880.949
ET0.52610.4710.6670.9990.69
GBDT0.95210.9710.98110.976
LR0.6130.950.6470.7590.9070.745
RF0.76910.8240.8890.9960.87
Table 4 Performance of the models for testing set (all features)
Model
Precision
Sensitivity
Specificity
Accuracy
AUROC
F1 score
XGBoost0.750.750.8570.8180.8890.75
ET0.66710.6670.80.8330.8
GBDT0.66710.6670.80.870.8
LR0.80.6670.8890.80.7410.727
RF0.6250.8330.6670.7330.9070.714